Table 2.
Correlation between the clinicopathologic characteristics and nuclear expression of CDKL2 protein in glioma
| Characteristics | n | CDKL2 (%) | P | |
|---|---|---|---|---|
|
| ||||
| Positive expression | Negative expression | |||
| Gender | 0.699 | |||
| Male | 85 | 39 (45.9) | 46 (54.1) | |
| Female | 59 | 29 (49.2) | 30 (50.8) | |
| Age | 0.230 | |||
| ≥ 50 | 34 | 13 (38.2) | 21 (61.8) | |
| < 50 | 110 | 55 (50.0) | 55 (50.0) | |
| Histologic Type | 0.029* | |||
| Astrocytic tumors | 98 | 39 (39.8) | 59 (60.2) | |
| Oligodendrogial tumors | 16 | 11 (68.8) | 5 (31.2) | |
| Other | 30 | 18 (60.0) | 12 (40.0) | |
| WHO Grade | 0.035* | |||
| I+II | 63 | 36 (57.1) | 27 (42.9) | |
| III+IV | 81 | 32 (39.5) | 49 (60.5) | |
| Tumor Location | 0.018* | |||
| Frontal | 44 | 19 (43.2) | 25 (56.8) | |
| Temporal | 26 | 8 (30.8) | 18 (69.2) | |
| Parietal | 18 | 12 (66.7) | 6 (33.3) | |
| Occipital | 9 | 1 (11.1) | 8 (88.9) | |
| Cerebellum | 9 | 6 (66.7) | 3 (33.3) | |
| Other | 38 | 22 (57.9) | 16 (42.1) | |
| Necrosis | 0.486 | |||
| Absent | 55 | 28 (50.9) | 27 (49.1) | |
| Present | 89 | 40 (44.9) | 49 (55.1) | |
| KI-67 expression | 0.038* | |||
| Positive | 87 | 35 (40.2) | 52 (59.8) | |
| Negative | 57 | 33 (57.9) | 24 (42.1) | |
*
P < 0.05 was considered significant.